Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for AF Maintenance in Hypertension (SPONSoR)
NCT06204640Phase 3
Key facts
- Status
- Not yet recruiting
- Start
- Mar 2024
- Primary completion
- Jan 2028
- Sponsor
- CHU Caen Normandie
- Modality
- Small Molecules
- Drugs
- spironolactone
- Conditions
- Atrial fibrillation (AFib)
01
Overview
Phase 3, randomised, open-label trial in Atrial fibrillation (AFib) comparing Spironolactone with Standard of Care (2 arms). Primary endpoint: Atrial Fibrillation Recurrence at 12 months. Planned start Mar 2024; status: not yet recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
Spironolactone
Spironolactone + Standard of Care
Standard of Care
Standard of Care alone
03
Endpoints
Primary
Atrial Fibrillation Recurrence
Secondary
Symptomatic Atrial Fibrillation Recurrence
Delay of Atrial Fibrillation Recurrence
Atrial Fibrillation Burden
Major Adverse Cardiovascular Events
Cerebral/Systemic Thrombo-embolic and Bleeding Events
Atrial Fibrillation Heart Rate
Blood Pressure
Safety of Spironolactone
Beyond the preview
Go deeper on NCT06204640.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06204640.